|Bid||50.70 x 1800|
|Ask||50.96 x 3100|
|Day's Range||50.59 - 51.06|
|52 Week Range||13.11 - 51.06|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.57|
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended J
Amgen narrowed its outlook for 2022 sales after its second-quarter beat. But Amgen stock fell just a fraction on Friday.